Dennis Karl Huang
Known title: EVP & Chief Tech Ops OfficerCIK: 0001641217
Associated companies
Transaction History
| RARE | ▲ Buy | Grant | 23,116 | $0 | 4/16/2026 | View on chart |
| RARE | ▼ Sell | Tax Withholding | 999 | $23K | 3/2/2026 | View on chart |
| RARE | ▲ Buy | Grant | 11,137 | $0 | 3/1/2026 | View on chart |
| RARE | ▼ Sell | Tax Withholding | 1,348 | $58K | 3/3/2025 | View on chart |
| RARE | ▲ Buy | Grant | 14,494 | $0 | 3/1/2025 | View on chart |
| RARE | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 | View on chart |
| RARE | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 | View on chart |
| RARE | ▲ Buy | Grant | 957 | $0 | 3/1/2024 | View on chart |
| RARE | ▼ Sell | Tax Withholding | 470 | $25K | 3/1/2024 | View on chart |
| RARE | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 | View on chart |
| RARE | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 | View on chart |
| RARE | ▼ Sell | Open Market | 389 | $18K | 3/1/2023 | View on chart |
| RARE | ▼ Sell | Other | 10,599 | $484K | 3/1/2023 | View on chart |
| RARE | ▼ Sell | Open Market | 3,234 | $215K | 3/1/2022 | View on chart |
| RARE | ▲ Buy | Grant | 14,000 | $0 | 3/1/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 358 | $29K | 10/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale
Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.